Ocugen, Inc. (OCGN) Financial Statements
Ocugen, Inc. (OCGN) reported trailing twelve-month revenue of $4.6M (down 3.6% year on year) and net income of -$81.8M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$61.0M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
OCGNOcugen, Inc.Follow OCGN — free
—
Price chart with a free account
- Market cap
- 250.8M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2020 Dec 20 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Revenue | 0.0 | 2.5 | 6.0 | 4.1 | 4.4 | 4.6 | |
| Research & development | 6.4 | 56.2 | 39.6 | 32.1 | 39.8 | 43.8 | |
| Operating income | -21.3 | -89.1 | -65.5 | -54.8 | -62.9 | -68.9 | |
| Pre-tax income | -21.8 | -86.8 | -63.1 | -54.1 | -67.8 | -81.8 | |
| Income tax | — | 0.0 | 0.0 | 0.0 | 0.0 | — | |
| Net income | -21.8 | -86.8 | -63.1 | -54.1 | -67.8 | -81.8 | |
| Diluted EPS ($) | -0.31 | -0.40 | -0.26 | — | — | — | |
| Diluted shares (mn) | 112.2 | 214.6 | 244.3 | — | — | — |
USD millions · SEC XBRL
Ocugen, Inc. — questions
- What is Ocugen, Inc.'s revenue?
- $4.6M over the twelve months to 2026-06-30, down 3.6% year on year, from its 10-Q and 10-K filings.
- What is Ocugen, Inc.'s net income?
- -$81.8M over the twelve months to 2026-06-30.
- What is Ocugen, Inc.'s free cash flow?
- -$61.0M over the twelve months to 2026-06-30.
Every figure on this page comes from Ocugen, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.